ProQR Therapeutics NV
NASDAQ:PRQR
ProQR Therapeutics NV
Research & Development
ProQR Therapeutics NV
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Research & Development
-€45.4m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-8%
|
|
|
Pharming Group NV
AEX:PHARM
|
Research & Development
-$88.4m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-21%
|
|
|
Uniqure NV
NASDAQ:QURE
|
Research & Development
-$134.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-9%
|
|
|
argenx SE
XBRU:ARGX
|
Research & Development
-$1.4B
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-51%
|
|
|
Merus NV
NASDAQ:MRUS
|
Research & Development
-$328.5m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-35%
|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Research & Development
-$28.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
ProQR Therapeutics NV
Glance View
ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. The company is headquartered in Leiden, Zuid-Holland. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. The company designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
See Also
What is ProQR Therapeutics NV's Research & Development?
Research & Development
-45.4m
EUR
Based on the financial report for Sep 30, 2025, ProQR Therapeutics NV's Research & Development amounts to -45.4m EUR.
What is ProQR Therapeutics NV's Research & Development growth rate?
Research & Development CAGR 10Y
-8%
Over the last year, the Research & Development growth was -36%. The average annual Research & Development growth rates for ProQR Therapeutics NV have been 5% over the past three years , -1% over the past five years , and -8% over the past ten years .
